CN103110697B - Pharmaceutical composition with hypoglycemic effect - Google Patents
Pharmaceutical composition with hypoglycemic effect Download PDFInfo
- Publication number
- CN103110697B CN103110697B CN201310039207.5A CN201310039207A CN103110697B CN 103110697 B CN103110697 B CN 103110697B CN 201310039207 A CN201310039207 A CN 201310039207A CN 103110697 B CN103110697 B CN 103110697B
- Authority
- CN
- China
- Prior art keywords
- extract
- parts
- pharmaceutical composition
- fructus
- diabetes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a pharmaceutical composition with a hypoglycemic effect. The pharmaceutical composition comprises the following components in parts by weight: 50-150 parts of dogwood extract, 60-50 parts of burdock extract, 40-110 parts of bitter melon extract, 35-90 parts of astragalus extract, 30-75 parts of pueraria extract, 35-75 parts of cinnamon extract, 4-13 parts of chromium-enriched yeast and 2-8 parts of magnesium stearate. The pharmaceutical composition disclosed by the invention can be prepared into any clinically acceptable appropriate medicament preparation according to a conventional preparation method in the art after addition of auxiliary materials or a carrier which are repaired for preparation formation in the pharmaceutical composition. Pharmacological test results show that the pharmaceutical composition has good hypoglycemic effect, and is non-toxic to animals, free of side effects and safe to take.
Description
Technical field
The present invention relates to a kind of drug regimen, relate in particular to a kind of pharmaceutical composition that there is hypoglycemic activity, controls diabetic complication, belong to hypoglycemic medicine composition field.
Background technology
Diabetes are to act on that body causes hypoinsulinism, insulin resistant etc. and a series of metabolism disorder syndromes such as the sugar that causes, protein, fat, power and water Xie Zhi by inherited genetic factors, immunologic function disorder, infected by microbes and toxin thereof, free radical toxin, Nervous and Mental Factors etc.
The clinical manifestation of diabetes is hyperglycemia and glycosuria.There is the symptoms such as polyphagia, polydipsia, polyuria, xerostomia and general weakness in patient, belongs to the category that the traditional Chinese medical science is quenched one's thirst.Diabetes and cancer, cardiovascular and cerebrovascular disease are regarded as worldwide three large diseases equally.
The world today, along with the acceleration of rapid development of economy and process of industrialization, the threat that human health faces noninfectious increases just day by day, and diabetes prevalence and diabetics quantity sharply rise.Diabetes and complication thereof have been brought serious burden to human health and social development.
According to IDF statistics, in the whole world in 2000, have diabetics 1.51 hundred million, and diabetics has reached 2.85 at present, by current growth rate, estimate that the year two thousand thirty whole world will have nearly 500,000,000 people to suffer from diabetes.
According to World Health Organization (WHO), disclose, the whole world just has 1 people to die from diabetes in every 10 seconds, within every 30 seconds, just has 1 people because of diabetes amputation, the complication such as blind, cardiovascular and cerebrovascular vessel in addition, and diabetes have become serious public health problem.
Diabetes have been not only developed country's " affluenza ", comprise that the developing country of China has also become the severely afflicated area of diabetes.Because China is the country that world population is maximum, its huge population base makes China bear diabetes burden greatly, and diabetics number accounts for 1/3 of global diabetics sum.
The pathogenic process of diabetes complexity makes the mankind not yet find so far the method for radical cure, and this just means that needs of patients receives treatment all the life, but regrettably, even in developed country, 2/3 the patient of also having an appointment can not get effective management.The diabetics of the long-term poor blood glucose control various complication that occur together threaten greatly patient's life and quality of life, to family and patient individual, have brought heavy financial burden.
Diabetes harm humans life security, psychological problems, the social problem of causing thus also become increasingly conspicuous.Therefore, relevant expert points out, " diabetes are no longer diabetics personal questions, especially a global problem.”
Hypoglycemic medicine still be take Western medicine clinically as main at present, but because of it, has many untoward reaction such as hypoglycemia and gastrointestinal reaction, and the target of therefore finding high-efficiency low-toxicity hypoglycemic medicine urgently realizes.
Research in recent years is found, Chinese medicine hypoglycemic activity is gentle lasting, and untoward reaction is few, and the mechanism of action has manifold effect, multidigit point and the feature such as multi-functional, can improve developing of carbohydrate tolerance and effective diabetes-alleviating complication, be a new approach of development blood sugar lowering new drug.
With respect to day by day huge suitable crowd's quantity, blood sugar lowering and prevent diabetes and complication thereof become the emphasis of scientist's research, find the key that medicine effective and that be free from side effects is research, Chinese medicine, with the feature such as its treating both the principal and secondary aspects of a disease, side effect be little, is more and more subject to the attention of domestic and international researcher.
TCM Treatment of Diabetes has the history of thousands of years, has recorded Chinese medicine and the compound preparation thereof of a large amount for the treatment of diabetes in medical book, therefore from Chinese traditional herbs, researchs and develops novel Chinese medicine preparation for treating diabetes and has great importance and wide prospect.
The pharmaceutical composition that the present invention has effect of lowering blood sugar extracts the effective ingredient that is rich in blood sugar lowering control sugar from multiple natural plants, research and Therapeutic Principle thereof based on Chinese medicine to hyperglycemia disease mechanism, simultaneously according to pharmaceutical research achievement, from source, control blood glucose, meet international up-to-date healthy trend.
The drug regimen composition formula that the present invention has an effect of lowering blood sugar has more the effect of control sugar, blood sugar lowering, hyperglycemia population life-time service its to control sugared effect more obvious, blood sugar reducing function is more reliable.
The present invention has the pharmaceutical composition of hypoglycemic activity, belongs to the Chinese medicine extract of integration of edible and medicinal herbs, without any side effects, blood sugar level in control agent, reduces hyperglycemia, and can not cause hypoglycemic reaction steadily, be applicable to diabetics life-time service, can not produce dependency and drug resistance.
Summary of the invention
The object of the invention is to provide a kind of pharmaceutical composition with hypoglycemic activity, and by zoopery, evaluates the function of blood sugar reduction of this hypoglycemic drug combination.
Another object of the present invention is to provide the preparation method of this drug regimen.
The present invention seeks to be achieved through the following technical solutions.
The object of the invention is to provide a kind of pharmaceutical composition with effect of lowering blood sugar, and this pharmaceutical composition is mainly comprised of each component of following weight portion: Fructus Corni extract 50-150 part, the 60-150 of Fructus Arctii extract part, Fructus Momordicae charantiae extract 40-110 part, Radix Astragali extract 35-90 part, Radix Puerariae extract 30-75 part, Cortex Cinnamomi extract 35-75 part, Rich chromium yeast 4-13 part, magnesium stearate 2-8 part.
In order to reach better therapeutic effect, preferably, the weight portion of each component is: Fructus Corni extract 70-130 part, the 70-140 of Fructus Arctii extract part, Fructus Momordicae charantiae extract 50-95 part, Radix Astragali extract 40-80 part, Radix Puerariae extract 35-70 part, Cortex Cinnamomi extract 40-70 part, Rich chromium yeast 6-12 part, magnesium stearate 3-7 part.
Preferred, the weight portion of each component is: Fructus Corni extract 100-115 part, the 85-120 of Fructus Arctii extract part, Fructus Momordicae charantiae extract 60-85 part, Radix Astragali extract 50-70 part, Radix Puerariae extract 40-65 part, Cortex Cinnamomi extract 45-65 part, Rich chromium yeast 7-9 part, magnesium stearate 4-6 part.
For reaching best therapeutic effect, the weight portion of each component is: 110 parts of Fructus Corni extracts, 105 parts of Fructus Arctii extract, 68 parts of Fructus Momordicae charantiae extracts, 62 parts of Radix Astragali extracts, 53 parts of Radix Puerariae extracts, 55 parts of Cortex Cinnamomi extracts, 8 parts of Rich chromium yeasts, 5 parts of magnesium stearate.
" diabetes " are the diseases of the easy overheap of glucose in a kind of blood, and diabetes are divided the diabetes of type i diabetes, type ii diabetes, gestational diabetes and other specific types.In diabetics, the shared ratio of type ii diabetes is about 95%.
The ability that produces insulin in diabetics body not completely loses, and in some patient bodies, insulin even produces too much, but the action effect of insulin has a greatly reduced quality, so the insulin in patient body is a kind of relative shortage.
Current, still lack the medicine that effects a radical cure diabetes, although hyperglycemia can be effectively controlled in orally-taken blood sugar reducing medicine and insulinize, the prevention of chronic complicating diseases and treatment are still lacked to effective measures.
The traditional Chinese medical science thinks, diabetes spp is in diabetes category, and its pathogenesis is YIN fluid deficiency, dryness-heat being excessive in the interior, and the deficiency of YIN is this, scorching is mark.，
Therefore, QI invigorating, yin nourishing, heat clearing away become the fundamentum that instructs " quenching one's thirst " (diabetes) of doctor's treatment at all times, ancient medicine document has been recorded much Chinese medicine can treat diabetes, and research shows that Chinese medicine has certain advantage in the treatment of diabetic complication.
Insulin in hyperglycemia patient body is a kind of relative shortage, and the easy overheap of glucose in blood, finally causes hyperglycemia.
The experimentation of Chinese medicine hypoglycemic activity has obtained larger progress, and confirmed that plurality of Chinese can be by promoting insulin secretion, increase insulin sensitivity, affect Insulin receptor INSR, the approach such as the absorption of promotion glucose and glycogenolysis are brought into play the hypoglycemic effect of falling.
Pharmaceutical composition of the present invention has mainly been prepared burden: Fructus Corni extract, Fructus Arctii extract, Fructus Momordicae charantiae extract, Radix Astragali extract, Radix Puerariae extract, Cortex Cinnamomi extract, Rich chromium yeast, magnesium stearate.Formula is unique, effect is remarkable, according to diabetes patient's pathogeny, carries out specific aim adjusting, systematicness conditioning, and tonification combination, has obvious blood sugar reducing function.
Type ii diabetes is polygenic inheritance factor and the coefficient complex disease of environmental factors.β emiocytosis defect and insulin resistant are two principal elements in pathogenesis.
Cortex Cinnamomi extract: the pharmacological Mechanism of Cortex Cinnamomi blood sugar reducing function is mainly by protection, stimulates beta Cell of islet to increase the content of serum insulin; Increase the sensitivity of insulin, improve insulin resistant ability, contribute to the metabolism of glucose in body; Remove free radical, anti peroxidation of lipid; Promote insulin secretion, increase the content of serum insulin.
From the fruit of Fructus Momordicae charantiae, isolate in recent years multiple saponin, protein, alkaloid, steroid class, terpenoid etc., there is the effects such as anti-diabetic, antiviral and antitumor.
Fructus Momordicae charantiae extract: isolated bitter gourd polypeptide can regulate Small Intestinal Brush Border Membrane Vesicles to the intake of glucose and stimulate the picked-up of Skeletal Muscle Cell to glucose, its mechanism and insulin-like from Fructus Momordicae charantiae and Semen Momordicae Charantiae.
Fructus Momordicae charantiae exchanges by affecting β metabolic defect in cellular calcium ion and hydrion, thereby upset cell membrane function, reaches promotion insulin secretion.By increasing glucose oxidase, decompose, activate glucose metabolism and suppress the absorption of glucose in intestinal, thereby produce blood sugar reducing function.。
Fructus Momordicae charantiae suppresses on the one hand glyconeogenesis key enzyme and produces blood sugar reducing function, and the oxidation of strengthening on the other hand glucose by activating glucose _ 6-phosphate dehydrogenase of alternative pathway utilizes.Fructus Momordicae charantiae not only can promote glucose tolerance in mice and insulin tolerance, but also scalable Phosphorylation of insulin receptor level and downstream signaling molecule thereof, thereby improve body insulin resistant.
The alcohol extract of Fructus Corni not only has obvious hypoglycemic activity to alloxan and the sick rat of epinephrine glycosuria, and the formed diabetes rat of streptozotocin (STZ) is also had to similar effect, but normal rat blood sugar is had no significant effect.
Experiment shows: the ursolic acid of Fructus Corni powder, ether extract and further separation all can reduce blood glucose, glucose in urine, amount of drinking water and voided volume significantly, illustrate that ursolic acid is Fructus Corni diabetes active component. there is report to point out, with the experiment of rat epididymis fatty tissue, find that Fructus Corni has ILA. Fructus Corni tannic acid can suppress lipid peroxidation, stop steatolysis, also can suppress epinephrine and adrenocortical hormone and promote fat-splitting effect.
Hypoglycemic activity can play by Inhibiting α-glucosidase activity in Fructus Arctii extract.Burdock extract can reduce rat blood sugar significantly for a long time, and improves the dosis tolerata to carbohydrate.
Diabetes patient 70% can develop into nephropathy infringement in 5 years.The anti-nephropathy of Fructus Arctii energy, suppresses the effect of the excretion of urine protein, and diabetic nephropathy is had to certain therapeutical effect; In addition its can be antibacterial, antiviral, raising immunity, diabetes ward mate is hypoimmunity often, easy diseases caused by exogenous pathogenic factor, Fructus Arctii is highly profitable to this
Puerarin is the main component of isoflavone in legume pueraria lobata root dry root.Mild action through its multipath, many target spots is sticked and gathering at clinical antiplatelet, improves Hemorheology state, and expansion artery blood vessel regulates blood fat, and the aspects such as blood sugar lowering have embodied uniqueness and definite curative effect.
Radix Puerariae can reduce blood glucose and the glycolated hemoglobin of alloxan and streptozotocin rat, improves serum insulin levels, and puerarin can also strengthen the sensitivity of histiocyte to insulin.
Radix Puerariae can be blocked the contraction of receptor,β to blood vessel, and blood vessel dilating alleviates the effect to glucagon hormone (epinephrine, glucocorticoid etc.), improves insulin sensitivity.Can also improve microcirculation, reduce whole blood viscosity, improve cell calcium-magnesium-ATPase activity, promote sugar and the transportation of insulin cross-film.
Radix Astragali replenishing QI to invigorate the spleen, modern study shows, and the Radix Astragali has dual regulation to blood glucose, and Radix Astragali saponin can be by promoting beta Cell of islet excreting insulin performance hypoglycemic activity, and astragalus polysaccharides has protective effect to the cardiac muscle of diabetes.
The active component astragalus polysaccharides of the Radix Astragali, can alleviate endoplasmic reticulum and damage by improving the er stress of liver, increases glycogen synthetase active, increases insulin signaling albumen synthetic quantity and activity, thus performance antidiabetic effect.
Chinese medicine astragalus can strengthen and adjust immunoreation effect, has inducing diuresis to remove edema, prevents or reverse urine protein effect, can delay fibrosis, the hardening process of renal tissue, and Progress of Diabetic Nephropathy is had to certain preventive effect.
The current research of Astragalus in Treating diabetes shows, astragalus polysaccharides is the macromolecular compound having compared with strong biological activity, oral or lumbar injection astragalus polysaccharides no matter, can obviously reduce body weight, blood glucose and the insulin resistance index of KKAy Mouse, can also improve impaired glucose tolerance, slim the abdomen, increase insulin sensitivity, but do not affect insulin secretion.
Trivalent chromium is that safest human body one of must trace element, manyly about chromium, the research of diabetes effect is thought: trace element chromium and diabetes are in close relations.
Chromium is mainly to strengthen insulin function to glycometabolic effect.In relying on the tissue of insulin, even if only have the increase of milli trace chromium, insulin function will obviously improve; Chromium Deficiency of Intake, health can increase the demand of insulin.
Trivalent chromium is the center active component of glucose tolerance factor.Scarce chromium is to cause diabetes, atherosclerotic pathogenic factor.Scarce chromium can make impaired glucose tolerance, insulin affinity reduce, β cellular sensitivity reduces, Insulin receptor INSR reduces, and blood glucose is too high or too low.Above-mentionedly extremely after chromium supplement, can be corrected.
Rich chromium yeast can reduce the blood glucose of diabetics, also can improve its hypoglycemic reaction, has the dual regulation effect to blood glucose, can effectively control diabetes, eliminates the abnormal phenomena of glucose tolerance aspect.
Various raw materials required for the present invention, specification all meets national medical standard, can obtain from managing company or manufacturer's purchase of Related product.
Each component in pharmaceutical composition of the present invention is pure natural plant extract, without incompatibility.
Each component in pharmaceutical composition of the present invention, according to this area or conventional formulation method, be prepared into any acceptable suitable drugs preparation clinically, it can be for example oral formulations, wherein, described oral formulations includes but not limited to tablet, granule, capsule, powder, pill, oral liquid, syrup or drop pill etc., is preferably capsule.
Pharmacology test result shows, pharmaceutical composition of the present invention is blood sugar lowering, control sugar effectively.Animal, without toxicity, side effect, is taken to safety.
The usage of pharmaceutical composition of the present invention and consumption: 3 times on the oral one, each 2, also can be according to everyone concrete condition, 2 times on the oral one, each 1-2 grain, every content 0.45g.
The specific embodiment
Further describe by the following examples the present invention, it should be understood that these embodiment, only for the object of illustration, never limit the scope of the invention.
Test material:
The present invention's raw material used has Fructus Corni extract, Fructus Arctii extract, Fructus Momordicae charantiae extract, Radix Astragali extract, Radix Puerariae extract, Cortex Cinnamomi extract, Rich chromium yeast and magnesium stearate.
The present invention crude drug Jun Kecong used Chinese medicine extract manufacturer and medical material manufacturer or distributor locate to buy and obtain, the compound national standard of crude drug specification, and supplier's qualification, certificate are complete.
Embodiment 1
The preparation of capsule
Take each component:: 110 parts of Fructus Corni extracts, 105 parts of Fructus Arctii extract, 68 parts of Fructus Momordicae charantiae extracts, 62 parts of Radix Astragali extracts, 53 parts of Radix Puerariae extracts, 55 parts of Cortex Cinnamomi extracts, 8 parts of Rich chromium yeasts, 5 parts of magnesium stearate.
Mix, pack 0# capsule into, obtain; Every heavy 0.45g.
Embodiment 2
The preparation of powder agent
130 parts of Fructus Corni extracts, 140 parts of Fructus Arctii extract, 95 parts of Fructus Momordicae charantiae extracts, 80 parts of Radix Astragali extracts, 70 parts of Radix Puerariae extracts, 70 parts of Cortex Cinnamomi extracts, 12 parts of Rich chromium yeasts, 7 parts of magnesium stearate.
By above-mentioned each component mix homogeneously, packing, obtains, and every packed amount is 900mg.
Embodiment 3
The preparation of granule
70 parts of Fructus Corni extracts, 70 parts of Fructus Arctii extract, 50 parts of Fructus Momordicae charantiae extracts, 40 parts of Radix Astragali extracts, 35 parts of Radix Puerariae extracts, 40 parts of Cortex Cinnamomi extracts, 6 parts of Rich chromium yeasts, 3 parts of magnesium stearate.
By above-mentioned each component mix homogeneously, granulation, packing, obtains, and every packed amount is 900mg.
The capsule of the pharmaceutical composition of the present invention of use-case 1 preparation carries out the pharmacology test of function of blood sugar reduction.
1. materials and methods
1.1 tested materials: adopt the prepared capsule of the embodiment of the present invention 1,0.45g/ grain.
1.2 laboratory animal
Secondary Kunming kind female mice, body weight 24-28g.
By Military Medical Science Institute's Experimental Animal Center, provided the quality certification number: SCXK-(army) 2001-0010051423.
1.3 experimental animal feeding environment
Feedstuff is provided by Military Medical Science Institute's Experimental Animal Center, the SPF level experimental animal room quality certification number: No. 015th, the moving word of doctor, room temperature 21.0-22.3 ℃, relative humidity 50-62%.
1.4 dosage group selections and tested material give mode
Three dosage groups and a model control group.It is 0.225g/kg.BW (low dosage), 0.45g/kg.BW (middle dosage), 1.35g/kg.BW (high dose) that three dosage group dosage is respectively 5 times, 10 times, 30 times of human body recommended dose.Take respectively tested material 1.125g, 2.25g, 6.75g, with distilled water, be assigned to 100ml, as the tested material of basic, normal, high three dosage groups, model control group gives equivalent distilled water.Establish two intact animal's groups simultaneously, give respectively high dose tested material and distilled water.
Per os gives tested material, and gavage amount is 20ml/kg.BW.
1.5 key instruments and reagent
Alloxan, purchased from U.S. Sigma company
Medisence Optium blood glucose meter, is produced by U.S. Abbott Laboratories company limited.
Abbott Laboratories' (ANTU) blood sugar test paper, is produced by U.S. Abbott Laboratories company limited.
1.6 test method
1.6.1 reduce fasting glucose experiment
1.6.1.1 intact animal
Select 20 of Healthy female mices, fasting 5 hours, gets tail blood and surveys blood glucose value.According to blood sugar level, be divided at random 2 groups, 10 every group, be respectively high dose group, Normal group.High dose group gives tested material, and normal dose group gives distilled water, and gavage amount: 20ml/kg.BW gives after 30 days fasting 5 hours continuously, gets tail blood and surveys fasting blood sugar, relatively two treated animal blood glucose values.
1.6.1.2 hyperglycemia model animal
Select the Healthy female mice fasting of body weight 24g-28g after 24 hours, tail vein gives alloxan 40mg/kg (administered dose 10ml/kg.BW), and after 6 days, fasting is 5 hours, gets tail blood and surveys blood glucose value.Blood glucose value is hyperglycemia model success animal at 10mmol/L～25mmol/L.According to blood sugar level, be divided at random 4 groups, 10 every group, be respectively model control group, low dose group, middle dosage group and high dose group.Dosage group gives the tested material of respective concentration, and model control group gives distilled water, and gavage amount: 20ml/kg.BW gives after 30 days fasting 5 hours continuously, gets tail blood and surveys fasting blood sugar, relatively each treated animal blood glucose value and blood glucose decline percentage rate.
Blood glucose value * 100% before blood glucose decline percentage rate=(the rear blood glucose value of blood glucose value-test before experiment)/experiment
1.6.2 resistance to sugar amount experiment
Laboratory animal reduces fasting glucose experiment (hyperglycemia model animal).Dosage group gives the tested material of respective concentration, model control group gives distilled water, gavage amount: 20ml/kg.BW, give continuously after 30 days fasting 5 hours, dosage group gives the tested material of respective concentration again, model control group gives distilled water, within 20 minutes, by mouth, give glucose 2.0g/kg, get tail hematometry to glucose after the blood glucose value (blood glucose value of 0 hour can be used as fasting blood sugar) of 0,0.5,2 hour, computation model matched group and dosage group group give the variation of each time point Area under the curve of blood glucose after glucose, as resistance to sugar amount observation index.
Area under the curve of blood glucose=0.25 * (0 hours blood glucose value+3 * 2, hours blood glucose value+4 * 0.5 hours blood glucose value)
1.7 respectively organize data all adopts SPSS11.5FOR WINDOWS to carry out systematic analysis.Wherein intact animal adopts T-check, and animal pattern adopts variance analysis and check between two, and as heterogeneity of variance, person adopts data transaction, still unevenly after conversion adopts rank test.
2, result
2.1 impacts on laboratory animal body weight: (in Table 1,2)
The impact of table 1 tested material on normal Mouse Weight
The impact of table 2 tested material on hyperglycemia model Mouse Weight
From table 1,2, each dosage treated animal weightening finish is compared with corresponding matched group, and there are no significant for difference (P > 0.05).
Illustrate that tested material has no significant effect normal mouse and hyperglycemia model Mouse Weight.
2.2 impacts on normal mouse fasting glucose
Table 3 tested material is on the impact of normal mouse fasting glucose (mmol/L)
From table 3, per os gave the tested material of 1.35g/kg.BW (high dose) after 30 days, and normal mouse fasting glucose is compared with Normal group, no significant difference (P > 0.05).
Illustrate that tested material has no significant effect normal mouse fasting glucose.
2.3 impacts on hyperglycemia model mice fasting glucose
Table 4 tested material is on hyperglycemia model mice fasting glucose and the percentile impact that declines
From table 4, with the tested material gavage hyperglycemia model mice of various dose after 30 days, three dosage group fasting glucose are all lower than model control group, and each dosage group blood glucose decline percentage rate is all higher than model control group, and difference all has significance (P < 0.05).
Tested material can significantly reduce the fasting glucose of alloxan induced hyperglycemia model mice.
2.4 impacts that the resistance to sugar of diabetic mice is measured
The impact of table 5 tested material on the resistance to sugar amount of diabetic mice
From table 5, with the tested material gavage hyperglycemia model mice of various dose, after 30 days, each time point Area under the curve of blood glucose of middle and high dosage group is lower than model control group, and difference has significance (P < 0.05).
A certain amount of tested material has the effect that strengthens the resistance to sugar amount of hyperglycemia mice.
3. brief summary
With the tested material gavage mice of various dose, after 30 days, each dosage treated animal weightening finish is compared with corresponding matched group, and there are no significant for difference (P > 0.05); In normal mouse, the fasting glucose of high dose group is compared with Normal group, no significant difference (P > 0.05); In model mice, three dosage group fasting glucose are all lower than model control group, and each dosage group blood glucose decline percentage rate is all higher than model control group, and difference all has significance (P < 0.05); In the test of resistance to sugar amount, each time point Area under the curve of blood glucose of middle and high dosage group is lower than model control group, and difference has significance (P < 0.05).Show that tested material has function of blood sugar reduction.
Prompting hypoglycemic drug combination of the present invention under this experiment condition has hypoglycemic effect.
The foregoing is only preferred embodiment of the present invention, is only illustrative for the purpose of the present invention, and nonrestrictive; in the spirit and scope that limit in the claims in the present invention, can carry out many changes to it; revise, even equivalence, but all can fall within the scope of protection of the present invention.
Claims (7)
1. a drug regimen with hypoglycemic activity, it is characterized in that, by each component of following weight portion, formed: Fructus Corni extract 50-150 part, the 60-150 of Fructus Arctii extract part, Fructus Momordicae charantiae extract 40-110 part, Radix Astragali extract 35-90 part, Radix Puerariae extract 30-75 part, Cortex Cinnamomi extract 35-75 part, Rich chromium yeast 4-13 part and magnesium stearate 2-8 part.
2. according to the drug regimen of claim 1, it is characterized in that, the weight portion of each component is: Fructus Corni extract 70-130 part, the 70-140 of Fructus Arctii extract part, Fructus Momordicae charantiae extract 50-95 part, Radix Astragali extract 40-80 part, Radix Puerariae extract 35-70 part, Cortex Cinnamomi extract 40-70 part, Rich chromium yeast 6-12 part and magnesium stearate 3-7 part.
3. according to claim 2 pharmaceutical composition, it is characterized in that, the weight portion of each component is: Fructus Corni extract 100-115 part, the 85-120 of Fructus Arctii extract part, Fructus Momordicae charantiae extract 60-85 part, Radix Astragali extract 50-70 part, Radix Puerariae extract 40-65 part, Cortex Cinnamomi extract 45-65 part, Rich chromium yeast 7-9 part and magnesium stearate 4-6 part.
4. according to the drug regimen of claim 1-3 any one, it is characterized in that: add after the needed adjuvant of preparations shaping or carrier, according to this area conventional formulation method, be prepared into any acceptable suitable drugs preparation clinically.
5. according to the drug regimen of claim 4, it is characterized in that: described pharmaceutical preparation is tablet, capsule, granule, powder, pill, oral liquid or syrup.
6. according to the drug regimen of claim 5, it is characterized in that: described pharmaceutical preparation is capsule.
7. the drug regimen described in claim 1-4 any one has the purposes of the pharmaceutical composition of hypoglycemic activity in preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310039207.5A CN103110697B (en) | 2013-02-01 | 2013-02-01 | Pharmaceutical composition with hypoglycemic effect |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310039207.5A CN103110697B (en) | 2013-02-01 | 2013-02-01 | Pharmaceutical composition with hypoglycemic effect |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103110697A CN103110697A (en) | 2013-05-22 |
| CN103110697B true CN103110697B (en) | 2014-10-22 |
Family
ID=48409100
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310039207.5A Active CN103110697B (en) | 2013-02-01 | 2013-02-01 | Pharmaceutical composition with hypoglycemic effect |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103110697B (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103655707A (en) * | 2013-12-23 | 2014-03-26 | 张杰明 | Hypoglycemic health-care product |
| CN103989835A (en) * | 2014-05-08 | 2014-08-20 | 北京昊源康科技有限公司 | Composition for reducing blood sugar, decreasing blood fat and protecting liver and preparation method and application thereof |
| CN103989168B (en) * | 2014-05-23 | 2015-08-26 | 天津大学 | A kind of hypoglycemic composition |
| CN106420955A (en) * | 2016-11-29 | 2017-02-22 | 汤臣倍健股份有限公司 | Traditional Chinese medicine composition with blood glucose reduction assistance effect, preparation method and product of traditional Chinese medicine composition |
| CN107412721B (en) * | 2017-09-15 | 2020-11-24 | 李玉保 | Blood sugar-reducing bitter gourd polypeptide compound capsule and preparation method thereof |
| CN109007785A (en) * | 2018-09-26 | 2018-12-18 | 上饶市康可得生物科技有限公司 | A kind of auxiliary hyperglycemic blood fat reducing healthcare food |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1296830A (en) * | 2000-11-24 | 2001-05-30 | 徐忠廷 | Chinese-medicinal capsule for treating diabetes |
| CN1324627A (en) * | 2000-05-19 | 2001-12-05 | 牛爱军 | Diabetes treating medicine and its prepn. method |
| CN101040911A (en) * | 2007-04-27 | 2007-09-26 | 山东省医学科学院基础医学研究所 | Chinese traditional medicine capsule preparation for treating and preventing diabetes and the method of preparing the same |
| CN101085039A (en) * | 2007-06-18 | 2007-12-12 | 长春现代中药专业技术服务中心有限公司 | Composition for preventing and treating diabetes (hyperglycaemia) and its preparation method |
| CN101695376A (en) * | 2009-10-14 | 2010-04-21 | 寇开勤 | Health-care food for preventing diabetes |
| CN101708295A (en) * | 2009-12-04 | 2010-05-19 | 卢速江 | Chinese medicinal preparation for treating diabetes and preparation methods thereof |
| CN101829160A (en) * | 2010-05-06 | 2010-09-15 | 广东省食品工业研究所 | Functional composition with functions of controlling blood sugar and enhancing nutrition |
-
2013
- 2013-02-01 CN CN201310039207.5A patent/CN103110697B/en active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1324627A (en) * | 2000-05-19 | 2001-12-05 | 牛爱军 | Diabetes treating medicine and its prepn. method |
| CN1296830A (en) * | 2000-11-24 | 2001-05-30 | 徐忠廷 | Chinese-medicinal capsule for treating diabetes |
| CN101040911A (en) * | 2007-04-27 | 2007-09-26 | 山东省医学科学院基础医学研究所 | Chinese traditional medicine capsule preparation for treating and preventing diabetes and the method of preparing the same |
| CN101085039A (en) * | 2007-06-18 | 2007-12-12 | 长春现代中药专业技术服务中心有限公司 | Composition for preventing and treating diabetes (hyperglycaemia) and its preparation method |
| CN101695376A (en) * | 2009-10-14 | 2010-04-21 | 寇开勤 | Health-care food for preventing diabetes |
| CN101708295A (en) * | 2009-12-04 | 2010-05-19 | 卢速江 | Chinese medicinal preparation for treating diabetes and preparation methods thereof |
| CN101829160A (en) * | 2010-05-06 | 2010-09-15 | 广东省食品工业研究所 | Functional composition with functions of controlling blood sugar and enhancing nutrition |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103110697A (en) | 2013-05-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103110697B (en) | Pharmaceutical composition with hypoglycemic effect | |
| CN102428832B (en) | Fungal pharmaceutical mycoplasm with blood sugar lowering efficacy and preparation method thereof | |
| CN103285231A (en) | Medicine composition for diabetes adjunctive therapy and preparation method thereof | |
| CN101091765A (en) | Medicinal comsns-and usage for preventing and treating diabets mellitus | |
| CN102600212B (en) | Medicinal health product for immunity enhancement and adjuvant treatment of tumor | |
| CN102526478B (en) | Formula of health-care medicine with functions of strengthening immunity and reducing blood sugar | |
| CN102935116A (en) | Pharmaceutical compositions or health care product having blood sugar reduction effect | |
| CN108524814A (en) | A kind of Chinese medicine composition and preparation method thereof for reducing blood glucose | |
| CN102205095A (en) | Medicinal composition with auxiliary blood sugar reducing effect | |
| CN100493572C (en) | Composition of medication for treating diabetes | |
| CN103816278B (en) | Composition for reducing blood sugar and application thereof | |
| CN102861201A (en) | Medicine composition for treating diabetes and preparation method thereof | |
| CN104606487A (en) | Fermented traditional Chinese medicine preparation as well as preparation method and application thereof | |
| CN102940782B (en) | Chinese medicinal composition for reducing blood sugar | |
| CN103055176B (en) | Traditional Chinese medicine for treating diabetes mellitus and preparation method thereof | |
| CN101954034B (en) | Chinese medicinal preparation for treating acquired immune deficiency syndrome and preparation method thereof | |
| CN101804123A (en) | Plant raw material composition with anti-fatigue effect, preparation method, application and product thereof | |
| CN103520684B (en) | Traditional Chinese medicine compound for reducing blood sugar | |
| CN102755568B (en) | Health-care product for assisting in decreasing blood sugar and preparation method thereof | |
| CN1327879C (en) | Medicine for treating diabetes and its preparing method | |
| CN102114185B (en) | Medicament for treating insulin resistance of type 2 diabetes | |
| CN101961478A (en) | Medicament for treating hyperosteogeny, rheumatism and rheumatoid diseases and preparation method thereof | |
| CN110680861A (en) | A Chinese medicinal composition for treating diabetes | |
| CN107007748A (en) | Improve Chinese medicine composition, medicine of physically weak symptom and its preparation method and application | |
| CN103536879A (en) | Pharmaceutical composition for treating diabetes mellitus and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |